Mze782

Phase 2

MMaze Therapeutics

Mze782 is one of 2 therapeutic programs targeting Phenylketonuria (PKU). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Phenylketonuria (PKU)Recruiting

Phenylketonuria (PKU)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Phenylketonuria (PKU)

#DrugCompanyPhaseTrials

Pegvaliase

BioMarin Pharmaceutical

Phase 3

1 2

Mze782

MMaze Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Phenylketonuria (PKU)

NCT07694440

Clinical

Trials by Indication[1]

Phenylketonuria (PKU)1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults With Phenylketonuria (PKU)

Recruiting·MMaze Therapeutics·Phase 2·NCT07694440·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mze782. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mze782. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Maze Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMaze Therapeutics

Mze782

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Phenylketonuria (PKU)1 trial

References

Drug Info

Quick Facts

Related News